在接受多巴胺激动剂治疗的前乳腺瘤男性中,从低阴性主义中恢复
Stefan Matei Constantinescu1, Dominique Maiter2, Orsalia Alexopoulou2
1Department of Endocrinology and Nutrition, Cliniques Universitaires Saint- Luc, 10 Avenue Hippocrate, Brussels, UCLouvain, 1200, Belgium. Stefan.m.constantinescu@saintluc.uclouvain.be.
Pituitary
|August 19, 2024
概括
患有前乳腺瘤的男性的水平通常在多巴胺激动剂 (DA) 治疗的第一年内恢复. 对于那些经过六个月的DA治疗后患有大瘤或低丸激素的人来说,可以考虑更早的丸激素替代.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
背景情况:
- 脑下垂体瘤 (prolactinoma) 通常会导致男性的阴性腺瘤.
- 多巴胺激动剂 (DA) 是对益生菌瘤的主要治疗方法.
研究的目的:
- 为了研究DA治疗的益生菌瘤男性的淋巴腺轴的恢复.
- 为了确定丸激素水平恢复的时间表和预测因素.
主要方法:
- 在接受DA治疗的97名患有益生菌瘤的男性进行了回顾性分析.
- 排除标准包括:原发性性阴性腺,在DA开始后12个月内进行手术,小瘤或低基线益生素水平.
- 在诊断时,患者被分为正常 (NT) 和低 (LT) 组.
主要成果:
- 在DA治疗6个月内,水平在NT和LT组显著增加 (分别p<0.05和p<0.001).
- 总体而言,在6个月后,阴道腺的恢复率为43%,在12个月后为50%,在24个月后为54%.
- 在12个月的持续性阴性恋症是由基线视野缺陷和较低的丸激素水平预测. 6个月后丸激素水平<7.4nmol/l是一个强烈的预测者,预示着1年后持续性阴性双胞胎症 (91%的灵敏度,94%的特异性).
结论:
- 在DA治疗的第一年,大多数患有前乳腺瘤的男性的水平会恢复.
- 在DA治疗6个月后,对于患有大,压缩性瘤或持续低水平 (<7.4nmol/l) 的患者,可以考虑更早地进行替代疗法.
相关概念视频
01:24Parkinson's Disease: Treatment
240
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
240
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
287
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
287
01:15Parkinson's Disease: Overview
501
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
501
01:15Hypoglycemia and Glucagon
224
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
224
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
238
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
238
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K